Prevalence of hepatitis C virus infection among men who have sex with men with human immunodeficiency virus-1 infection between 2010 and 2020 in Japan: A single-center retrospective cohort study
- PMID: 36585274
- DOI: 10.1016/j.jiac.2022.11.009
Prevalence of hepatitis C virus infection among men who have sex with men with human immunodeficiency virus-1 infection between 2010 and 2020 in Japan: A single-center retrospective cohort study
Abstract
Introduction: The high prevalence of hepatitis C virus (HCV) infection in human immunodeficiency virus (HIV)-positive men who have sex with men (MSM) is an important health issue. The purpose of this study is to investigate the actual prevalence of HCV infection among HIV-positive MSM in Japan.
Methods: This study is a single-center retrospective cohort study. We collected data of HIV-infected MSM who visited our hospital from January 2010 to December 2020, and evaluated HCV prevalence, course of HCV infection, and direct-acting antiviral (DAA) treatment efficacy in HIV-infected MSM.
Results: Overall, 1135 HIV-infected MSM had HCV antibody (Ab) tests during the observation period. The first anti-HCV Ab positive rate in HIV-infected MSM was 4% (45/1135), and the seroconversion rate of HCV antibody was 3.6% (39/1090). Treponema pallidum hemagglutination antigen positivity (odds ratio [OR], 5.28; 95% confidence interval [CI], 2.9 to 10.5) and intravenous drug injection (OR, 19; 95% CI, 3.4 to 149) were identified as factors associated with HCV Ab positivity. Spontaneous elimination of HCV infection was observed in 17.9% (7/39) of patients. DAA treatment was performed in 43 cases, and the overall sustained virologic response 12 (SVR12) rate for DAA treatment was 93% (40/43).
Conclusion: A high HCV infection rate among HIV-infected MSM was observed in Japan. The DAA treatment response rate in patients with HIV/HCV co-infection was the high response rate.
Keywords: Hepatitis C virus; Human immunodeficiency virus; MSM; SVR.
Copyright © 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare no conflicts of interest relevant to this article.
Similar articles
-
A Treatment-as-Prevention Trial to Eliminate Hepatitis C Among Men Who Have Sex With Men Living With Human Immunodeficiency Virus (HIV) in the Swiss HIV Cohort Study.Clin Infect Dis. 2021 Oct 5;73(7):e2194-e2202. doi: 10.1093/cid/ciaa1124. Clin Infect Dis. 2021. PMID: 32761122
-
Microelimination or Not? The Changing Epidemiology of Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in France 2012-2018.Clin Infect Dis. 2021 Nov 2;73(9):e3266-e3274. doi: 10.1093/cid/ciaa1940. Clin Infect Dis. 2021. PMID: 33400777
-
Recently acquired hepatitis C virus infection among people living with human immunodeficiency virus at a university hospital in Taiwan.World J Gastroenterol. 2021 Oct 7;27(37):6277-6289. doi: 10.3748/wjg.v27.i37.6277. World J Gastroenterol. 2021. PMID: 34712032 Free PMC article.
-
Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it?J Int AIDS Soc. 2018 Apr;21 Suppl 2(Suppl Suppl 2):e25062. doi: 10.1002/jia2.25062. J Int AIDS Soc. 2018. PMID: 29633560 Free PMC article. Review.
-
Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression.Lancet HIV. 2022 Jun;9(6):e414-e427. doi: 10.1016/S2352-3018(22)00077-7. Lancet HIV. 2022. PMID: 35659336
Cited by
-
Injection drug use and sexually transmitted infections among men who have sex with men: A retrospective cohort study at an HIV/AIDS referral hospital in Tokyo, 2013-2022.Epidemiol Infect. 2023 Nov 15;151:e195. doi: 10.1017/S0950268823001772. Epidemiol Infect. 2023. PMID: 37965724 Free PMC article.
-
Prevalence of hepatitis B and C infections among HIV-positive men who have sex with men: A systematic review and meta-analysis.Health Sci Rep. 2024 Jun 26;7(6):e2206. doi: 10.1002/hsr2.2206. eCollection 2024 Jun. Health Sci Rep. 2024. PMID: 38933421 Free PMC article.
-
Effectiveness of glecaprevir/pibrentasvir in HIV/HCV-coinfected patients treated with bictegravir/emtricitabine/tenofovir alafenamide.Clin Exp Hepatol. 2024 Sep;10(3):165-169. doi: 10.5114/ceh.2024.141752. Epub 2024 Jul 29. Clin Exp Hepatol. 2024. PMID: 39697370 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical